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Abstract-In the present study, we used the Langendorff 
technique to evaluate the involvement of endothelin-1 (ET-1) 
and nitric oxide (NO) in coronary vasoconstriction and 
myocardial depression in hearts isolated from 
lipopolysaccharide (LPS)-treated rats. Coronary perfusion 
pressure (CPP) increased markedly in hearts from LPS -treated 
rats. Pretreatment with BQ-123, an ET-1 type A receptor 
antagonist, significantly reduced the increase in CPP induced 
by LPS. LPS induced a marked decrease in left ventricular 
developed pressure, the product of left ventricular developed 
pressure and heart rate, as well as the maximal rate of rise/fall 
of left ventricular pressure. Pretreatment with BQ -123 
partially reversed the LPS-induced cardiac depression. 
Administration of BQ-123 and AMG, an inhibitor of iNOS, 
prior to LPS challenge significantly blocked the negative 
inotropic effect. These results suggest that ET-1 augments the 
NO-mediated cardiac contractile depression induced by LPS 
and the accompanying increase in coronary resistance. 
Keywords-Coronary perfusion pressure, contraction, 
LPS, nitric oxide, endothelin 
I .  INTRODUCTION 
The isolated heart has been used widely as a model to 
explore the actions of drugs that affect cardiovascular 
efficiency. The Langendorff technique is a classical means 
of measuring the contractile status of the myocardium. 
Coronary perfusion pressure in the Langendorff system is an 
important parameter that reflects the effects drugs on 
coronary artery resistance. 
Cardiovascular dysfunction induced by 
lipopolysaccharide (LPS) has long been of great concern. 
LPS, an integral part of the outer layer of the gram-negative 
bacterial cell wall, stimulates a systemic inflammatory 
process and the production of proinflammatory cytokines 
and vasoactive mediators [1,2]. Endothelin-1 (ET-1) and 
nitric oxide (NO) are known to markedly increase during 
LPS challenge [3]. But no direct experimental evidence 
from the isolated heart (i.e., in the absence of neural and 
humoral factors) has clarified the interaction between ET -1 
and NO in the coronary arterial and cardiac inotropic 
response after LPS treatment. 
In the present study, we used the Langendorff 
preparation to investigate the roles of ET -1 and NO in L P S  
induced coronary vasoconstriction and cardiac depression. 
11. METHODOLOGY 
(I)  Preparation of isolated rat hearts 
All experiments were carried out on male Sprague- 
Dawley rats (240-300g). Immediately after decapitation, the 
heart was rapidly excised and rinsed in 4OC Krebs-Henseleit 
buffer (composition in mM: NaCl 118, NaHCQ 25, KC14.7, 
MgS04 1.2, CaClz 1.4, KH2P04 1.1, glucose 11, pH 7.4) 
maintained at 37°C and gassed with 95% Q l S %  C Q .  
Within 1 min the heart m s  mounted on the Langendorff 
apparatus, and perfused at a constant flow (8ml. min-I). 
(2) Experimental setup and data processing 
A .  Experimental setup 
The coronary perfusion pressure (CPP) was 
continuously recorded by a pressure transducer connected to 
a computer. A fluid-filled latex balloon was introduced 
through the mitral valve into the left ventricle. The balloon 
was connected via a short plastic tube to another pressure 
transducer and computer for measurement of left ventricular 
developed pressure (LVDP), heart rate (HR), and maximal 
rate of rise/fall of ventricular pressure (+/-dFVdtmax). 
B. The principle of coronary perfusion pressure 
measurement 
G 
Perfusion pressure (AP) 
Fig 1. Relationships between pressure, flow and vascular 
resistance 
In the present study the heart was perfused at a constant 
flow of 8ml min-l and the CPP in the perfusion tubing was 
continuously recorded. Under the constant flow, the pressure 
reflects the resistance of the coronary artery. 
C. Experimental protocols 
Rats received a bolus intraperitoneal injection of LPS 
(1Omg kg-I). After 4h, the animals were killed and the hearts 
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rapidly excised for ex vivo perfusion by the Langendorff 
technique (LPS ,group). 
In experiments examining the effects of endothelin, the 
selective ET- 1 type A receptor antagonist BQ- 123 (03x1 0- 
h o l  kg-') was given 15 min before the LPS injection and 4h 
later the animals were killed for isolated heart perfusion 
(BQ- 123 +LPS group). 
To investigate the effeck of nitric oxide, 
aminoguanidine (AMG) (lOOmg kg-I), an inhibitor of 
inducible nitric oxide synthase (iNOS), was given 
immediately before injection of BQ123. 15 min later LPS 
was administered. The hearts were removed for isolated 
perfusion 4h after LPS challenge (AMG+BQ-l23+LPS 
Separate sets of hearts from rats not exposed to LPS 
group) 
served as controls. 
D. Data analysis and statistics 
Data were expressed as mean+SD. Comparisons 
between multiple groups were made by one-way ANOVA 
followed by the Student-Newman-Keuls post hoc test 
Pc0.05 was considered statistically significant. 
A. Involvement of endothelin-1 in LPSinduced coronary 
vasoconstriction 
Exposure to LPS caused a marked rise in CPP 
compared with controls (n=8). This response was 
maintained over a prolonged period (at least 60 min). The 
vasoconstriction following LPS exposure was abolished by 
pretreatment with B Q  123 (0.8x1U6mol kg-', n=7), while 
BQ-123 had no significant effect in control hearts. In 
addition, there was no significant change in CPP in the 
AMGtBQ-I23+LPS group vs the BQ- I23+LPS group (Fig. 
2). 
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Fig. 2. The effect of BQ- 123 with or without Ah4G on the increase of CPP 
induced by LPS. Data expressed as mean*SD, n=7 S. **p<O.OI, LPS and 
AMGtLPS groups vs control; ##p<O.OI, BQ-l23+LPS and AMWBQ- 
123+LPS groups vs LPS group 
B. Effects of ET-I and NO on the contraction of isolated rat 
hearts following LPS challenge 
LPS challenge depressed cardiac contractile function. 
LVDP, the product of LVDP and HR (LVDPxHR) and 
MP/dtmax decreased markedly. Treatment with B Q  123 
alone prior to LPS administration partially reversed the 
inhibitory action of LPS on (cardiac contraction. B Q  123 in 
the presence of AMG (100mg kg-') significantly blocked the 
cardiac depression induced by LPS exposure (Fig. 3.). 
120, 
100. 
f a@ 
60, 
40, 
20 
E L P S  -AMG+LPS 
25000 
3 
3 
20000 $ 
3. 
15000 ZI 
10000 
LVDP LVDP x HR 
0 Control 0 BQ-l23+LPS =BQ-l23+AMG+LPS 
D L P S  -AMG+LPS 
4000 1 
1000 
m 5 -1000 
6 -2000 
-3000 
- ## 
+dPldtmax 
Fig. 3. Effect of BQ-123 with or without AMG on LPSinduced cardiac 
depression. Data expressed as meanSD, n=7-8. **p<O.OI vs control; 
##p<O.O 1 vs LPS group 
IV. DISCUSSION 
The isolated heart IS a classical experimental 
preparation used to define: the alterations of inotropic 
properties under pathological conditions without the 
complicating influences of autonomic innervation and 
circulating hormones. In the present study, according to the 
relationship Pressure =flow x resistance, we used isolated 
rat hearts perfused at a constant flow by the Langendorff 
technique to determine alterations in the coronary arterial 
response of hearts that had experienced LPS challenge. We 
found that administration of LPS caused a sustained increase 
in coronary perfusion pressure, which was significantly 
attenuated by administration of the ET- 1 type A receptor- 
selective antagonist BQ-123. It is known that ET-1 is a 
novel endotheliumderivetl vasoconstrictive peptide. 
Bacterial endotoxin and cytokine mediators released in 
response to endotoxin induce ET- 1 gene expression and 
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stimulate ET- 1 protein secretion [4]. In a number of species, 
LPS increases circulating ET-1 levels 2- to 10-fold in vivo 
[5]. The actions of ET-1 are mediated by ETA and ETB 
receptors. ETA is the principal constrictor receptor, whereas 
ETB has mixed actions: direct constriction and nitric oxide- 
dependent vasodilation. ETA receptors are the predominant 
receptors in the coronary arteries, accounting for > 85% of 
all ET receptors [q. Hori and his ceworkels also observed 
that rat coronary vasculature expresses the ETA receptor 
subtype [7]. Thus we used BQ-123, a highly specific ETA 
receptor antagonist to probe the effect of ET-1 in rat 
coronary arteries. It has been demonstrated that ET-1 
inhibits cytokine-induced iNOS mRNA expression [8] and 
dose-dependently inhibits cGMP production by the nitric 
oxide donor sodium nitroprusside [9]. Together, these lines 
of evidence indicate that the increase in coronary perfusion 
pressure induced by LPS exposure is due to a pronounced 
release of ET-1. 
Many studies have pointed out that LPS activates iNOS, 
which contributes to the myocardial depression 
accompanying sepsis [lo] [ l  11. Cardiac iNOS expression 
increases several hours after exposure to LPS, with a peak 
after 6h [12]. In the present study, these effects were 
significantly blocked by AMG, indicating that nitric oxide 
mediated the cardiac depression. The intracelluhr 
mechanism involves the stimulation of soluble guanylate 
cyclase to increase intracellular levels of cGMP with a 
subsequent reduction in intracellular calcium. Brady and his 
colleagues showed that the stable cGMP analogue, 8- 
bromoguanosine 3',5'-cyclic monophosphate, caused a 
concentration-related reduction in myocyte contractility and 
this effect was reversed by methylene blue, an inhibitor of 
guanylate cyclase [ 131. These findings further confirm that 
NO acts by elevating intracellular levels of cGMP. 
In the present study, we observed that pretreatment 
with BQ -1 23 partially reversed the negative inotropic effect 
induced by exposure to LPS. We have shown that LPS 
treatment induces the production of ET-1, leading to a 
marked and long lasting coronary vasoconstriction. Hence, 
the coronary resistance increased, which may cause 
myocardial ischemia and so depress cardiac function. Thus 
we predict that ameliorating the blood supply of coronary 
arteries would help to reverse the depression of cardiac 
contractility induced by LPS. In addition, the NO-mediated 
vasodilatation is somewhat endotheliumdependent [ 141, so 
a pronounced coronary resistance develops following 
endothelial injury. Also, because ET-1 is able to inhibit 
iNOS mRNA expression, we confirm that ET-1 causes 
coronary vasoconstriction as well as augmenting cardiac 
depression. 
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